Mir Scientific, New York, has been selected as a finalist in the Fierce Innovation Awards – Life Sciences Edition 2020, a peer-reviewed awards program from the publisher of Fierce Biotech and Fierce Pharma. Mir Scientific was recognized as a finalist in the category of Medical Device Innovation for its liquid biopsy urine test that can accurately detect and grade prostate cancer noninvasively. The competition highlights companies that demonstrate innovative life sciences solutions, technologies, and services that have the potential to make the greatest impact. The Mir Sentinel Prostate Test developed by Mir Scientific can, with over 90% accuracy, detect prostate cancer as well as classify the risk category of malignancies based on a single urine specimen and without the need for invasive biopsies. The awards program’s applications were reviewed by an exclusive panel of executives from major biotech and pharma companies including Astellas, Accenture, AstraZeneca, Angiocrine Bioscience, Biotech Research Group, NIHR Clinical Research Network, Medidata Solutions, and PPD. All applications were evaluated based on the following criteria: effectiveness, technical innovation, competitive advantage, financial impact, and true innovation. Winners will be announced in the 2020 Innovation Report set to publish by Fierce Life Sciences on September 14, 2020. “We are honored by the decision of the award committee to select Mir Scientific as a finalist for the Fierce Innovation Awards – Life Sciences Edition 2020,” says Sam Salman, chairman and CEO of Mir Scientific. “Our Mir Sentinel Prostate Test powers a comprehensive disease management platform that is accurate, noninvasive, standalone, and scalable. Aided by our proactive engagement with the urology and oncology communities, we have developed a game-changing technology that we are confident will forever change the standard of care for urological cancers.” The Mir Sentinel Test is expected to be commercially available in the United States later this year and in select markets in Europe and Asia beginning in 2021. For more information, visit Mir Scientific. Featured image: PC-3 human prostate cancer cells, stained with Coomassie blue, under differential interference contrast microscope.